Fengyuan Pharmaceutical (000153.SZ): Net profit of 47.0109 million yuan in the first quarter increased 2.14% year over year

On April 25, Ge Longhui Pharmaceutical (000153.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,121 billion yuan, down 7.08% year on year; net profit attributable to shareholders of listed companies was 47.0109 million yuan, up 2.14% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.6746 million yuan, up 4.96% year on year; basic earnings per share were 0.1,416 yuan.

Gelonghui FinanceApr 25 21:27

Express News | Fengyuan Pharmaceutical: Construction of the erythritol project has been completed and technical reforms are being implemented on the production line

BreakingsApr 22 18:07

Fengyuan Pharmaceutical (000153.SZ): The subsidiary Maanshan Fengyuan Pharmaceutical currently produces and operates normally

Gelonghui, April 22丨Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that Maanshan Fengyuan Pharmaceutical, a subsidiary of the company, currently produces and operates normally. The drug GMP compliance inspection is a compliance inspection applied for by Maanshan Fengyuan Pharmaceutical after increasing equipment through technical modifications due to insufficient production capacity in the atticaine production line; after the initial inspection did not pass, Maanshan Fengyuan Pharmaceutical re-formulated a plan for the inspection results and has now applied for a drug GMP compliance test again; after the compliance inspection is passed, the production capacity of Maanshan Fengyuan Pharmaceutical's atticaine products will be greatly increased.

Gelonghui FinanceApr 22 15:54

Express News | Fengyuan Pharmaceutical: Obtained two drug registration certificates

BreakingsMar 27 16:50

Fengyuan Pharmaceutical (000153.SZ) received two drug registration certificates

According to the Zhitong Finance App, Fengyuan Pharmaceutical (000153.SZ) issued an announcement. The company received the approval and issuance of peritoneal dialysis solution (lactate-G 2.5%), “Drug Registration Certificate” (certificate number: 2024S00438) and peritoneal dialysis solution (lactate-G 1.5%) and “Drug Registration Certificate” (certificate number: 2024S00439) from the State Drug Administration. The above drugs are suitable for patients with acute and chronic renal failure requiring continuous insular peritoneal dialysis treatment due to ineffectiveness of non-dialysis treatment.

Zhitong FinanceMar 27 16:32

Fengyuan Pharmaceutical (000153.SZ) obtained drug registration certificates for peritoneal dialysis solution (lactate-G 1.5%) and peritoneal dialysate (lactate-G 2.5%)

Gelonghui, March 27丨Fengyuan Pharmaceutical (000153.SZ) announced that recently, the company received the “Drug Registration Certificate” (certificate number: 2024S00438) for peritoneal dialysis solution (lactate-G 2.5%) and peritoneal dialysis solution (lactate-G 1.5%) and “Drug Registration Certificate” (certificate number: 2024S00439) approved and issued by the State Drug Administration. The peritoneal dialysis solution (lactate-G 1.5%) and peritoneal dialysis solution (lactate-G 2.5%), which the company has obtained a drug registration certificate this time, are suitable for abdominals requiring continuous sleepless nights due to ineffectiveness of non-dialysis treatment

Gelonghui FinanceMar 27 16:27